Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$26.1K Sell
931
-200
-18% -$5.33K 0.02% 233
2025
Q4
$28.2K Sell
1,131
-500
-31% -$12.6K 0.02% 247
2025
Q3
$41.6K Hold
1,631
0.03% 220
2025
Q2
$39.5K Buy
+1,631
New +$38K 0.03% 224
2024
Q3
$65.4K Hold
2,261
0.06% 160
2024
Q2
$63.3K Buy
+2,261
New +$62.2K 0.06% 157
2023
Q3
$93.9K Sell
2,830
-63
-2% -$2.23K 0.1% 116
2023
Q2
$106K Buy
+2,893
New +$113K 0.1% 110
2023
Q1
Sell
-4,288
Closed -$220K 319
2022
Q4
$220K Buy
+4,288
New +$206K 0.17% 89
2022
Q3
Sell
-4,412
Closed -$231K 309
2022
Q2
$231K Sell
4,412
-1,424
-24% -$72.6K 0.2% 77
2022
Q1
$302K Sell
5,836
-509
-8% -$26.4K 0.23% 77
2021
Q4
$375K Buy
6,345
+201
+3% +$9.96K 0.22% 81
2021
Q3
$264K Buy
6,144
+234
+4% +$10.4K 0.18% 86
2021
Q2
$231K Sell
5,910
-632
-10% -$24.6K 0.18% 78
2021
Q1
$237K Buy
+6,542
New +$232K 0.2% 81
2020
Q4
Sell
-8,397
Closed -$292K 106
2020
Q3
$292K Sell
8,397
-43,583
-84% -$1.53M 0.28% 61
2020
Q2
$1.93M Buy
+51,980
New +$1.77M 0.45% 46

Other funds holding PFE

WFA of San Diego's PFE Position: Q1 2026 in Review

WFA of San Diego reduced its Pfizer (PFE) stake by 18% in Q1 2026, selling an estimated $5.33K and leaving 931 shares worth $26.1K. The position accounts for 0.02% of the portfolio, ranked #233.

WFA of San Diego first reported a position in PFE in Q2 2020 and has held it in 17 quarters since. The position peaked at $1.93M in Q2 2020. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • WFA of San Diego held 931 shares of Pfizer worth $26.1K as of Q1 2026.
  • WFA of San Diego sold 200 Pfizer shares in Q1 2026, an estimated $5.33K.
  • Pfizer made up 0.02% of WFA of San Diego's portfolio in Q1 2026, its #233 holding.
  • WFA of San Diego first reported a position in Pfizer in Q2 2020 and has held it in 17 quarters since.
  • WFA of San Diego's Pfizer position peaked at $1.93M in Q2 2020.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on WFA of San Diego's 13F filing for Q1 2026, filed 11 May 2026.